Publications

Publications

Cyclacel has contributed to many scientific advancements.

Jul 2021

Kantarjian HM et al., Results of a Randomized Phase 3 Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS). Cancer 2021; doi: 10.1002/cncr.33828.


Mar 2021

Somarelli JA et al., A precision medicine drug discovery pipeline identifies combined CDK2 and 9 inhibition as a novel therapeutic strategy in colorectal cancer. Mol Cancer Ther. 2020, 19: 2516-2527.


Mar 2021

Lai LP et al., Sensitivity of oncogenic KRAS-expressing cells to CDK9 inhibition. SLAS Discovery. April 24, 2021; doi.org/10.1177/24725552211008853.


Dec 2020

Kawakami M et al., A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Mol Cancer Ther. 2021, 20:477-489.


Oct 2020

Do KT et al, Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin-dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). An oral presentation delivered at the 32nd EORTC/AACR/NCI Virtual Symposium 24-25 Oct 2020.


Oct 2020

Poon E et al., Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. J Clin Invest 2020; https://doi.org/10.1172/JCI134132.


Aug 2020

Decker JT et al., Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer. Cancer Biol & Therapy 2020; https://doi.org/10.1080/15384047.2020.1818518.


Jul 2020

Frame S et al., Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLOS One, July 9, 2020; doi.org/10.1371/journal.pone.0234103.


Apr 2020

Siebert S et al., Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial. Medicine 2020, 99:26.


Sep 2019

Blake DR et al., Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Science Signal. Jul 16, 2019, 12(590):eaav7259.


Learn More About Our Science

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.